A pilot study of interferon-alpha-2B dose reduction with dose optimization.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 May 2016
At a glance
- Drugs Interferon alpha-2b (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2015 Results (10 MU/m2 and 4 MU/m2 dosing levels) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 Apr 2015 Planned primary completion date changed from 1 Jan 2014 to 1 Jan 2016, according to ClinicalTrials.gov record.